Week Ending March 14, 2022

First Neoadjuvant Immunotherapy OK’d in Lung Cancer
“— FDA approves nivolumab plus chemotherapy in resectable, non-small cell lung cancer
The FDA approved nivolumab (Opdivo) in combination with chemotherapy as neoadjuvant treatment for adults with resectable non-small cell lung cancer (NSCLC), Bristol Myers Squibb announced.”

Patients With Lung Cancer Demonstrate Superior Resilience in the Face of COVID-19
“The general population experienced nearly double the amount of anxiety and depression that patients with non–small cell lung cancer reported during the COVID-19 pandemic.”

Q&A: What updated reimbursement policies could mean for CT lung screening rates in the United States
“Recent reimbursement rule changes for low-dose computed tomography (CT) lung screen scans are expected help open up screening for more patients, according to the American College of Radiology (ACR).”

Salk scientists receive 2022 Mark Foundation Endeavor Award to study lung cancer
“LA JOLLA—Professors Reuben Shaw, Susan Kaech, Christian Metallo and Alan Saghatelian have received a 2022 Mark Foundation for Cancer Research Endeavor Award to support their research exploring the metabolic changes that help lung cancers develop. The $3 million Endeavor Award promotes collaborative science to tackle some of the toughest challenges in cancer research. The Salk team—one of four teams chosen out of nearly 200 applications submitted by institutions around the world—hopes their work will lead to the development of more effective lung cancer treatments.”

OS Not Extended With Bevacizumab and Erlotinib in EGFR-Mutant NSCLC
“Adding bevacizumab to the use of erlotinib (Tarceva) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) did not prolong their survival. However, both treatment arms with and without bevacizumab (Avastin) had relatively long survival durations that encouraged researchers, according to study results published in the Lancet.1”

Medscape Education to Host Second Annual Perspectives in Lung Cancer Care Virtual Conference
“NEW YORK, March 11, 2022 /PRNewswire/ — Medscape Education will host the second annual Perspectives in Lung Cancer Care virtual conference from March 17-19. This conference is designed to help enhance clinician understanding of the spectrum of lung cancer and provide strategies that can help translate data updates into improvements in patient care.”

How Stigma Affects People with Lung Cancer
“As if a cancer diagnosis isn’t enough to deal with, many people with lung cancer also face stigma.”

How Does Lung Cancer Affect Appetite? 13 Tips to Combat Weight Loss
“If you’re living with lung cancer, you may see many changes in your physical and emotional health, such as a shift in your appetite.”

If You Notice This on Your Hands, Get Checked for Cancer
“Every year, over 230,000 new cases of lung cancer are diagnosed, and 130,000 individuals die from the disease. “Lung cancer is by far the leading cause of cancer death among both men and women, making up almost 25 percent of all cancer deaths,” warns the American Cancer Society.”

How palliative and respite care can help with non-small cell lung cancer
“People with late stage non-small cell lung cancer (NSCLC) and their caregivers may benefit from palliative and respite care, respectively.”

Getting the most out of life: Moving forward after lung cancer
“Not everyone knows what their neighborhood looks like at 4 in the morning, but Jeff Clark of Brooklyn does.”

Lung Cancer Survivor Reina Honts Is Fighting Back Against the Stigma: ‘You Have The Power To Change Your Future’
“When Reina Honts told her doctor she wanted to be screened for lung cancer, that doctor thought Honts “was a bit insane.”  Honts had no symptoms and was young, so she didn’t fit the standard lung cancer profile.”